Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H39N3O3 |
| Molecular Weight | 465.6276 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)C2=CC=CC(O)=C2)NC(=O)[C@H]3CC4=C(CN3)C=C(O)C=C4
InChI
InChIKey=ZLVXBBHTMQJRSX-VMGNSXQWSA-N
InChI=1S/C28H39N3O3/c1-18(2)26(30-27(34)25-13-20-8-9-24(33)12-21(20)15-29-25)17-31-11-10-28(4,19(3)16-31)22-6-5-7-23(32)14-22/h5-9,12,14,18-19,25-26,29,32-33H,10-11,13,15-17H2,1-4H3,(H,30,34)/t19-,25+,26+,28+/m0/s1
| Molecular Formula | C28H39N3O3 |
| Molecular Weight | 465.6276 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT01431586?term=JDTIC&rank=1
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT01431586?term=JDTIC&rank=1
JDTic demonstrated high affinity for the kappa opioid receptor in the binding assay and highly potent and selective kappa antagonism in the [(35)S]GTP-gamma-S assay. This drug was in phase I of clinical trials for the treatment of cocaine abuse, but development was stopped because of incidence of non-sustained ventricular tachycardia.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity. | 2010-07-22 |
|
| Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats. | 2010-06 |
|
| Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. | 2010-06 |
|
| Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. | 2010-06 |
|
| Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. | 2010-06 |
|
| Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). | 2009-12-10 |
|
| [11C]-MeJDTic: a novel radioligand for kappa-opioid receptor positron emission tomography imaging. | 2008-07 |
|
| Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). | 2008-03-27 |
|
| Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. | 2007-12 |
|
| In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. | 2007-10-13 |
|
| Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. | 2007-10-12 |
|
| Kappa receptor bivalent ligands. | 2007 |
|
| Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. | 2005-11-07 |
|
| Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. | 2005-11 |
|
| Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. | 2004-10-06 |
|
| Importance of phenolic address groups in opioid kappa receptor selective antagonists. | 2004-02-12 |
|
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. | 2003-07-03 |
|
| Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. | 2001-08-16 |
Patents
Sample Use Guides
In Vitro Use Guide
Curator's Comment: JDTic demonstrated high affinity for the κ receptor in the binding assay and highly potent and selective κ antagonism in the [35S]GTP-γ-S assay. In the [35S]GTP-γ-S functional assay, JDTic demonstrated a 3.4-fold increase in κ antagonist potency relative to the functional assay utilizing guinea pig membranes.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:01:16 GMT 2025
by
admin
on
Mon Mar 31 21:01:16 GMT 2025
|
| Record UNII |
3C6FZ6UXC8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
361444-66-8
Created by
admin on Mon Mar 31 21:01:16 GMT 2025 , Edited by admin on Mon Mar 31 21:01:16 GMT 2025
|
PRIMARY | |||
|
JDTIC
Created by
admin on Mon Mar 31 21:01:16 GMT 2025 , Edited by admin on Mon Mar 31 21:01:16 GMT 2025
|
PRIMARY | This study has been terminated.(No further subjects will be enrolled due to adverse events.) | ||
|
3C6FZ6UXC8
Created by
admin on Mon Mar 31 21:01:16 GMT 2025 , Edited by admin on Mon Mar 31 21:01:16 GMT 2025
|
PRIMARY | |||
|
DTXSID70433301
Created by
admin on Mon Mar 31 21:01:16 GMT 2025 , Edited by admin on Mon Mar 31 21:01:16 GMT 2025
|
PRIMARY | |||
|
9956146
Created by
admin on Mon Mar 31 21:01:16 GMT 2025 , Edited by admin on Mon Mar 31 21:01:16 GMT 2025
|
PRIMARY | |||
|
JDTIC
Created by
admin on Mon Mar 31 21:01:16 GMT 2025 , Edited by admin on Mon Mar 31 21:01:16 GMT 2025
|
PRIMARY | JDTic is a selective, long-acting ("inactivating") antagonist of the .KAPPA.-opioid receptor (KOR). JDTic is a 4-phenylpiperidine derivative, distantly related structurally to analgesics such as pethidine and ketobemidone, and more closely to the MOR antagonist alvimopan. In addition, it is structurally distinct from other KOR antagonists such as norbinaltorphimine. | ||
|
JDTIC
Created by
admin on Mon Mar 31 21:01:16 GMT 2025 , Edited by admin on Mon Mar 31 21:01:16 GMT 2025
|
PRIMARY | Kappa Antagonist JDTic in Phase 1 Clinical Trial |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
When JDTic was administered either s.c. or p.o. 24 h before the selective KOP (kappa)-opioid receptor agonist, enadoline, AD(50s) of 4.1 and 27.3, respectively, were obtained. A time-course study of JDTic versus enadoline indicated significant antagonist p.o. activity up to 28 days.
|
